Filter Type: All Time (0 Results) Past 24 Hours Past Week Past month Post Your Comments?
All Time (0 Results)
Past 24 Hours
Past Week
Past month
CAMBRIDGE, Mass., September 10, 2021--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Deborah Dunsire, M.D., to the Company’s Board of Directors. Dr.
Under the agreement, Syros will supply SY-5609, its highly selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7), for a combination dosing cohort in Roche’s ongoing Phase 1/1b INTRINSIC trial, which is evaluating multiple targeted therapies or immuno Will Syros Pharmaceuticals, Inc. (SYRS) Report Negative Q2 Earnings?